United States: Supreme Court Invalidates Personalized Medicine Patents on Grounds They Are Unpatentable Subject Matter Under Patent Act

Last Updated: May 14 2012
Article by Therese M. Finan

In a unanimous decision, the Supreme Court invalidated personalized medicine patents on grounds they are unpatentable subject matter under Section 101 of the Patent Act.

In a long-awaited decision addressing patentable subject matter, the Supreme Court invalidated patents directed to customizing methods of treatment. Mayo Collaborative Serv. v. Prometheus Labs, 566 U. S. ___ (2012). This was the second time in recent years that the Court opined on the scope of patentable subject matter under 35 U.S.C. § 101. See Bilski v. Kappos, 561 U.S. ___ (2010).

The patents at issue, U.S. Patent Nos. 6,355,623 and 6,680,302, pertained to methods of optimizing the therapeutic efficiency of thiopurine drugs in a patient suffering from an autoimmune disease. The Court's analysis focused on claim 1 of the '623 patent because the "other claims in the patents do not differ significantly from claim 1." Slip op. at 6. Claim 1 of the '623 recites as follows:

1. A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising:

  1. administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder; and
  2. determining the level of 6-thioguanine in said subject having said immune-mediated gastrointestinal disorder, wherein the level of 6-thioguanine less than about 230 pmol per 8 x 108 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject; and wherein the level of 6-thioguanine greater than about 400 pmol per 8 x 108 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject. '623 patent, col. 20, ll. 10-20 (emphasis added).

To reach its decision, the Court's analysis began with the well-established exclusionary rule that "laws of nature, natural phenomena and abstract ideas' are not patentable." Mayo, slip op at. 1 quoting Diamond v. Diehr, 450 U.S. 175, 185 (1981). The Court determined that the claims were directed to processes reciting laws of nature and, therefore, unpatentable. Slip op. at 8. In doing so, the Court overruled the Federal Circuit, which held that claims "do not encompass laws of nature or preempt natural correlations." See slip op. at 8.

The Court recognized that there must be some balance in the application of the exclusionary rule. "[T]oo broad an interpretation of this exclusionary principle could eviscerate patent law. For all inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas." Slip op at 2. Thus, "an application of a law of nature or mathematical formula to a known structure or process may be well deserving of patent protection." Id. quoting Diehr, 450 U.S. at 187 (emphasis in original). However, "to transform an unpatentable law of nature into patent-eligible application of such a law, one must do more than simply state the law of nature while adding the words." Id. at 3 (emphasis in original).

To determine the patentability of the claims, the Supreme Court posed the question:

whether the claims do significantly more than simply describe these natural relations. To put the matter more precisely, do the patent claims add enough to their statements of the correlations to allow the processes they describe to qualify as patent-eligible processes that apply natural laws?

Slip op. at 8. In answering the question "no," the Court noted that process claims reciting a law of nature are not patentable unless the claim "has additional features that provide practical assurance that the process is more than a drafting effort designed to monopolize the law of nature itself." Slip op. at 9. Simply reciting the law of nature with instructions to "apply the law" is insufficient. Id.

The Court found that the claims at issue lacked such additional features. "The process that each claim recites tells doctors interested in the subject about the correlations that the researchers discovered." Slip op. at 9. These correlations are specified in the "administering," "determining" and "wherein" steps. These steps while "not themselves natural laws" were insufficient "to transform the nature of the claim" to render the claim patentable. Id. The "administering step" was insufficient because it merely refers to a specific audience – i.e. doctors treating patients with the drug. As the court noted, "the prohibition against patenting abstract ideas cannot be circumvented by attempting to limit the use of the formula to a particular environment." Slip op. at 9 citing to Bilski, slip op. at 14. Similarly, the "wherein" steps were insufficient because they "tell a doctor about the relevant natural laws, at most adding a suggestion that he should take those laws into account when treating a patient." Id. Since the "determining" step merely recites commonly practiced conventional activity by those in the field, it was also insufficient to impart patentability. Such "[p]urely 'conventional or obvious' '[pre]solution activity' is normally not sufficient to transform an unpatenable law of nature into a patent eligible-application of such law." Id. at 10, quoting Parker v. Flook, 437 U.S. 584, 590 (1978). Similarly, the combination of the three steps also was insufficient:

"the claims inform a relevant audience about certain laws of nature; any additional steps consist of wellunderstood, routine, conventional activity already engaged in by the scientific community; and those steps, when viewed as a whole, add nothing significant beyond the sum of their parts taken separately. For these reasons we believe that the steps are not sufficient to transform unpatentable natural correlations into patentable applications of those regularities." Id. at 11.

The Court also provided some guidance to patentable subject matter under Section 101. "[S]imply appending conventional steps, specified at a high level of generality to laws of nature, natural phenomena, and abstract ideas" does not render a claim patentable. Id. at 14. Integrating a mathematical formula, which alone would be unpatentable, into a process thereby "transform[ing] the process into an inventive application of the formula" is sufficient. Id. at 11. Similarly, process claims that contain both laws of nature and "several unconventional steps...that confine the claims to a particular, useful application of the principle" are also patentable. Id. at 15. The Court rejected the argument that the claims were transformations and reductions of an article to a different state and also refused to carve out new rules of patentable subject matter for diagnostic laws of nature. Id. at 19.

Although many have asserted the decision creates a significant uncertainty as to whether personalized medicine methods are patentable, it is worth noting that the U.S. Patent Office has already issued interim guidelines on the decision. Interestingly, the PTO states that the examiners "should continue to examine patent applications for compliance with section 101 using the existing interim Bilski guidance factoring additional considerations" discussed in Prometheus.

According to these guidelines, patentable claims "are not directed to an exception to the eligibility such that the claim amounts to a monopoly on the law of nature, natural phenomenon, or abstract idea itself." PTO Interim Guidelines at 2 (emphasis in original). Patentable claims "amount to significantly more than a law of nature, a natural phenomenon, or an abstract idea with conventional steps specified at a high level of generality appended thereto." Id. (emphasis in original). Claims drawn to an exception under 101 (i.e. laws of natural, natural phenomena or abstract ideas) should be rejected as being directed to non-statutory subject matter. Id. at 2-3. In response to such a rejection, applicants should explain why the claims are "not drawn solely to the exception and point to the limitations in the claim that apply the law of nature, natural phenomena or abstract idea." Id. at 3. The PTO is in the process of developing further detailed guidance on patentable subject matter under Section 101. Id.

In a subsequent decision, the Court vacated the judgment in Association for Molecular Pathology v. Myriad Genetics, Inc. and remanded the case to the Federal Circuit for further consideration in light of Mayo. The Myriad case was pending in the Supreme Court to address the patentability of DNA-based inventions. Recently the District Court for the District of Columbia invalidated a patent claiming a system and method to guide the selection of therapeutic treatments using a computer program relying on Prometheus. See SmartGene v. Advanced Biological Laboratories, No. 1:08-CV-0642 (BAH), 2012 WL 1059611, ___ F. Supp. 2d ___ (D.D.C., March 30, 2012).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.